Chemotherapy in Head and Neck Cancer Clinical Predictors of Tolerance and Outcomes

被引:12
作者
Kubicek, Gregory J. [1 ]
Kimler, Bruce F. [2 ]
Wang, Fen [2 ]
Reddy, Eashwer K. [2 ]
Girod, Douglas A. [3 ]
Williamson, Steven K. [4 ]
机构
[1] Univ Pittsburgh, Med Ctr, Dept Radiat Oncol, Pittsburgh, PA USA
[2] Univ Kansas, Med Ctr, Dept Radiat Oncol, Kansas City, KS 66103 USA
[3] Univ Kansas, Med Ctr, Dept Otolaryngol, Kansas City, KS 66103 USA
[4] Univ Kansas, Med Ctr, Dept Internal Med, Kansas City, KS 66103 USA
来源
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2011年 / 34卷 / 04期
关键词
head and neck cancer; chemotherapy; capsulation; tolerance; SQUAMOUS-CELL CARCINOMA; LOCALLY ADVANCED HEAD; RADIATION-THERAPY; CONCURRENT CHEMOTHERAPY; RANDOMIZED TRIAL; RADIOTHERAPY; CISPLATIN; CHEMORADIOTHERAPY; CARBOPLATIN; TIME;
D O I
10.1097/COC.0b013e3181e9c0a2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The addition of chemotherapy is more efficacious than radiation alone in the treatment of head and neck cancer (HNC). However, little data are available regarding the best chemotherapy agent and dosing, or factors associated with chemotherapy compliance. Methods: Retrospective review of all HNC patients receiving combined chemotherapy and radiotherapy at the University of Kansas Medical Center between 1994 and 2006. A total of 172 patients were analyzed in this report. Results: A total of 37% of patients were able to complete the entire chemotherapy regimen as intended. Multiple factors were examined in relation to chemotherapy completion and clinical outcome. Factors associated with not being able to complete chemotherapy on Cox regression analysis include use of a platinum agent and older age at diagnosis. No chemotherapy-related variables were prognostic for overall survival or disease-free survival. Conclusion: Factors associated with reduced chemotherapy compliance include older age and cisplatin agent. None of the chemotherapy characteristics (agent, total dose, and schedule) were associated with outcome.
引用
收藏
页码:380 / 384
页数:5
相关论文
共 16 条
[1]   Intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer [J].
Adelstein, DJ ;
Li, Y ;
Adams, GL ;
Wagner, H ;
Kish, JA ;
Ensley, JF ;
Schuller, DE ;
Forastiere, AA .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (01) :92-98
[2]   Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized intergroup study 0099 [J].
Al-Sarraf, M ;
LeBlanc, M ;
Giri, PGS ;
Fu, KK ;
Cooper, J ;
Vuong, T ;
Forastiere, AA ;
Adams, G ;
Sakr, WA ;
Schuller, DE ;
Ensley, JF .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) :1310-1317
[3]   Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer [J].
Ang, KK ;
Trotti, A ;
Brown, BW ;
Garden, AS ;
Foote, RL ;
Morrison, WH ;
Geara, FB ;
Klotch, DW ;
Goepfert, H ;
Peters, LJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 51 (03) :571-578
[4]   Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer [J].
Bernier, J ;
Domenge, C ;
Ozsahin, M ;
Matuszewska, K ;
Lefèbvre, JL ;
Greiner, RH ;
Giralt, J ;
Maingon, P ;
Rolland, F ;
Bolla, M ;
Cognetti, F ;
Bourhis, J ;
Kirkpatrick, A ;
van Glabbeke, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (19) :1945-1952
[5]   Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck [J].
Bonner, JA ;
Harari, PM ;
Giralt, J ;
Azarnia, N ;
Shin, DM ;
Cohen, RB ;
Jones, CU ;
Sur, R ;
Raben, D ;
Jassem, J ;
Ove, R ;
Kies, MS ;
Baselga, J ;
Youssoufian, H ;
Amellal, N ;
Rowinsky, EK ;
Ang, KK .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06) :567-578
[6]   Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer [J].
Brizel, DM ;
Albers, ME ;
Fisher, SR ;
Scher, RL ;
Richtsmeier, WJ ;
Hars, V ;
George, SL ;
Huang, AT ;
Prosnitz, LR .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (25) :1798-1804
[7]   Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck [J].
Cooper, JS ;
Pajak, TF ;
Forastiere, AA ;
Jacobs, J ;
Campbell, BH ;
Saxman, SB ;
Kish, JA ;
Kim, HE ;
Cmelak, AJ ;
Rotman, M ;
Machtay, M ;
Ensley, JF ;
Chao, KSC ;
Schultz, CJ ;
Lee, N ;
Fu, KK .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (19) :1937-1944
[8]   Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer [J].
Forastiere, AA ;
Goepfert, H ;
Maor, M ;
Pajak, TF ;
Weber, R ;
Morrison, W ;
Glisson, B ;
Trotti, A ;
Ridge, JA ;
Chao, C ;
Peters, G ;
Lee, DJ ;
Leaf, A ;
Ensley, J ;
Cooper, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (22) :2091-2098
[9]   RANDOMIZED COMPARISON OF CISPLATIN PLUS FLUOROURACIL AND CARBOPLATIN PLUS FLUOROURACIL VERSUS METHOTREXATE IN ADVANCED SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK - A SOUTHWEST-ONCOLOGY-GROUP STUDY [J].
FORASTIERE, AA ;
METCH, B ;
SCHULLER, DE ;
ENSLEY, JF ;
HUTCHINS, LF ;
TRIOZZI, P ;
KISH, JA ;
MCCLURE, S ;
VONFELDT, E ;
WILLIAMSON, SK ;
VONHOFF, DD .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (08) :1245-1251
[10]   Dose intensity comparison between weekly and 3-weekly Cisplatin delivered concurrently with radical radiotherapy for head and neck cancer: A retrospective comparison from New Cross Hospital, Wolverhampton, UK [J].
Ho, Kean F. ;
Swindell, Ric ;
Brammer, Caroline V. .
ACTA ONCOLOGICA, 2008, 47 (08) :1513-1518